FTC's bid to block Covetrus-MWI puts veterinary distribution, and PV information flow, in focus
The US suit against a $3.5bn merger of the two largest vet distributors is an antitrust case, but animal-health PV teams should check how safety information moves through the channel.
What happened
On 13 November 2026 the US Federal Trade Commission sued to block Covetrus's $3.5bn acquisition of veterinary distributor MWI. The agency says the deal would combine the two largest distributors to veterinary clinics and would raise prices and erode service quality across animal health supply.
The records do not say how the court case will proceed, whether the parties will contest it or amend the deal, or what timetable applies. Those points are not yet known. The FTC's announcement is framed around competition and pricing, and nothing in the record refers to pharmacovigilance.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources this analysis is based on
- FTC sues to block Covetrus's $3.5bn acquisition of veterinary distributor MWI FTC · Fri 13 Nov 2026
- Medline details repair and replace programme for recalled beds, rails, mattresses and accessories FDA MedWatch · Fri 13 Nov 2026
- PRAC publishes final EU-language translations of phenobarbital product information in targeted signal procedure EMA · PRAC · Fri 13 Nov 2026
- EMA page on veterinary signal management details phenobarbital review and updated MAH templates EMA · PRAC · Fri 13 Nov 2026
- EMA publishes draft veterinary PV guideline listing medically important VeDDRA terms EMA · Fri 13 Nov 2026
- EMA opens consultation on medically important VeDDRA terms list for veterinary pharmacovigilance EMA · Fri 13 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Vercise DBS instruction recall: why IFU corrections matter to trial teams
Health Canada's Type II recall of Vercise clinician programmer instructions is narrow, but it shows how a labelling correction can ripple into protocols, training and site files.
Denmark's Voltabak shortage to mid-May 2027 shows how fragile single-source supply is
DKMA's updated notice on Laboratoires Thea's diclofenac eye drops, with the Methergin withdrawal and estradiol patch notices, shows how Denmark manages supply failures.
Illinois Medicaid charges show no pharma link, but the compliance signal is worth reading
Illinois's attorney general has charged three people in two Medicaid fraud cases, with no stated link to medicines. For quality and compliance teams, the context around it matters more than the case.